References
Toft AD. Thyroxine therapy. N Engl J Med 1994; 331: 174–80
Bartalena L, Bogazzi F, Martino E. Adverse effects of thyroid hormone preparations and antithyroid drugs. Drug Saf 1996 Jul; 15(1): 53–63
British National Formulary No. 32. London: The Pharmaceutical Press, 1996 Sep: 297–9
Disorders of the thyroid gland. In: Grahame-Smith DG, Aronson JK, editors. Oxford Textbook of clinical pharmacology and drug therapy. Oxford: Oxford University Press, 1984: 432–8
Petersen K, Bengtsson C, Lapidus L, et al. Morbidity, mortality, and quality of life in patients treated with levothyroxine. Arch Intern Med 1990; 150: 2077–81
Biondi B, Fazio S, Carella C, et al. Cardiac effects of long-term thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol Metab 1993; 77: 334–8
Faber J, Galloe AM. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. Eur J Endocrinol 1994; 130: 350–6
Cohen JH, Ingbar SH, Braverman LE. Thyrotoxicosis due to ingestion of excess thyroid hormone. Endocr Rev 1989; 10: 113–24
Cooper DS. Antithyroid drugs. N Engl J Med 1984; 311: 1353–62
Arab DM. Malatjalian DA, Rittmaster RS. Severe cholestatic jaundice in uncomplicated hyperthyroidism treated with methimazole. J Clin Endocrinol Metab 1995; 80: 1083–5
Rights and permissions
About this article
Cite this article
Thyroid treatment: careful monitoring minimises adverse effects. Drugs Ther. Perspect 9, 13–16 (1997). https://doi.org/10.2165/00042310-199709050-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-199709050-00005